The estimated Net Worth of Jason Haddock is at least $2.39 Milhão dollars as of 16 February 2023. Jason Haddock owns over 8,750 units of Codiak BioSciences stock worth over $499 and over the last 8 years Jason sold CDAK stock worth over $2,386,722.
Sign up
Jason Haddock CDAK stock SEC Form 4 insiders trading
Jason has made over 8 trades of the Codiak BioSciences stock since 2017, according to the Form 4 filled with the SEC. Most recently Jason exercised 8,750 units of CDAK stock worth $499 on 16 February 2023.
The largest trade Jason's ever made was selling 96,712 units of Codiak BioSciences stock on 6 February 2019 worth over $2,108,322. On average, Jason trades about 14,174 units every 126 days since 2016. As of 16 February 2023 Jason still owns at least 8,750 units of Codiak BioSciences stock.
You can see the complete history of Jason Haddock stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jason Haddock's mailing address?
Jason's mailing address filed with the SEC is C/O MERUS N.V., UPPSALALAAN 17, UTRECHT, P7, 3584 CT.
Insiders trading at Codiak BioSciences
Over the last 4 years, insiders at Codiak BioSciences have traded over $15,220 worth of Codiak BioSciences stock and bought 11,821,475 units worth $20,798,957 . The most active insiders traders include Steven Gillis, Venture Fund Viii, L.P.Arch..., ePermanent Fund Corp Alaska. On average, Codiak BioSciences executives and independent directors trade stock every 25 days with the average trade being worth of $19,158. The most recent stock trade was executed by Yalonda Howze on 30 March 2023, trading 1,628 units of CDAK stock currently worth $326.
What does Codiak BioSciences do?
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What does Codiak BioSciences's logo look like?
Complete history of Jason Haddock stock trades at Merus N.V e Codiak BioSciences
Codiak BioSciences executives and stock owners
Codiak BioSciences executives and other stock owners filed with the SEC include:
-
Dr. Douglas Edward Williams Ph.D.,
Pres, CEO & Director -
Dr. Sriram Sathyanarayanan Ph.D.,
Chief Scientific Officer -
Yalonda Howze,
Exec. VP, Chief Legal Officer, Chief Compliance Officer & Corp. Sec. -
Dr. Benny Sorensen M.D., Ph.D.,
Member of Scientific Advisory Board & Consultant -
Dr. David J. Mauro M.D., Ph.D.,
Chief Medical Officer -
Dr. Benny Sorensen,
Member of Scientific Advisory Board & Consultant -
Richard Brudnick,
Chief Bus. Officer & Head of Corp. Strategy -
Nicole Barna,
Sr. VP of HR -
Christopher J. M. Taylor,
VP of Investor Relations & Corp. Communications -
Dr. Konstantin Konstantinov,
Chief Technology Officer -
Linda Cathavina Bain CPA,
CFO & Treasurer -
Arundathy N. Pandite,
Director -
Anne Virginie Eggimann,
Director -
Ventures Fund V General Par...,
-
Richard Brudnick,
See Remarks -
Venture Fund Viii, L.P.Arch...,
-
Charles L Cooney,
Director -
Kyriazi Theo Melas,
Director -
Briggs Morrison,
Director -
Eric S Lander,
Director -
Jason Haddock,
Director -
Karen Bernstein,
Director -
Steven Gillis,
Director -
Permanent Fund Corp Alaska,
-
Benny Sorensen,
See Remarks -
Nicole Barna,
See Remarks -
Jennifer J. Wheler,
Chief Medical Officer -
Ajay Verma,
See Remarks -
David J Mauro,
Chief Medical Officer -
Douglas E Williams,
President & CEO -
Konstantin Konstantinov,
Chief Technology Officer -
Linda Bain,
Chief Financial Officer -
Sriram Sathyanarayanan,
Chief Scientific Officer -
Yalonda Howze,
See Remarks